Active Ingredient(s): Ceritinib
FDA Approved: * April 29, 2014
Pharm Company: * NOVARTIS PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zykadia Overview

Ceritinib (INN,[2] trade name Zykadia /zakedi/ zy-KAY-dee-) is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC).[3] It was developed by Novartis and received FDA approval for use in April 2014.[3] Contents 1 Medical uses 2 Pharmacology 2.1 Mechanism of action 2.2 Adverse effects 2.3 Dose 3 Research and development 4 Commercialization 5 Intellectual property 6 See also 7 References 8 External links M...

Read more Zykadia Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ceritinib

Recent Zykadia Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 150mg
  • Tablet: 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zykadia: (2 results)

Sorted by National Drug Code
  • 0078-0640 Zykadia 150 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 0078-0694 Zykadia 150 mg Oral Tablet, Film Coated by Novartis Pharmaceuticals Corporation

Other drugs which contain Ceritinib or a similar ingredient: (1 result)